James P Allison
Overview
Explore the profile of James P Allison including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
219
Citations
39119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Mok S, Liu H, Agac Cobanoglu D, Anang N, Mancuso J, Wherry E, et al.
Proc Natl Acad Sci U S A
. 2025 Jan;
122(2):e2418985122.
PMID: 39786926
The effects of T cell differentiation arising from immune checkpoint inhibition targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) on the immunological memory response...
3.
Sultan H, Takeuchi Y, Ward J, Sharma N, Liu T, Sukhov V, et al.
Nature
. 2024 Jul;
632(8023):182-191.
PMID: 39048822
CD4 T cells can either enhance or inhibit tumour immunity. Although regulatory T cells have long been known to impede antitumour responses, other CD4 T cells have recently been implicated...
4.
Mok S, Agac Cobanoglu D, Liu H, Mancuso J, Allison J
Proc Natl Acad Sci U S A
. 2024 Jun;
121(27):e2404661121.
PMID: 38923991
Immune checkpoint therapies (ICT) improve overall survival of patients with cancer but may cause immune-related adverse events (irAEs) such as myocarditis. Cytotoxic T lymphocyte-associated antigen 4 immunoglobulin fusion protein (CTLA-4...
5.
Castro-Pando S, Howell R, Li L, Mascaro M, Faraoni E, Le Roux O, et al.
Cancer Immunol Res
. 2024 Jun;
12(9):1170-1183.
PMID: 38842383
IL17 is required for the initiation and progression of pancreatic cancer, particularly in the context of inflammation, as previously shown by genetic and pharmacological approaches. However, the cellular compartment and...
6.
Siddiqui B, Palaskas N, Basu S, Dai Y, He Z, Yadav S, et al.
Cancer Immunol Res
. 2024 May;
12(8):964-987.
PMID: 38768394
Immune checkpoint therapies (ICT) can induce life-threatening immune-related adverse events, including myocarditis and myositis, which are rare but often concurrent. The molecular pathways and immune subsets underlying these toxicities remain...
7.
Aparicio A, Tidwell R, Yadav S, Chen J, Zhang M, Liu J, et al.
Clin Cancer Res
. 2024 Apr;
30(13):2751-2763.
PMID: 38683200
Purpose: To determine the efficacy and safety of risk-adapted combinations of androgen signaling inhibitors and inform disease classifiers for metastatic castration-resistant prostate cancers. Patients And Methods: In a modular, randomized...
8.
Sharma N, Fan X, Atolagbe O, Ge Z, Dao K, Sharma P, et al.
J Exp Med
. 2024 Mar;
221(4).
PMID: 38517331
We have previously demonstrated synergy between ICOS costimulation (IVAX; ICOSL-transduced B16-F10 cellular vaccine) and CTLA-4 blockade in antitumor therapy. In this study, we employed CyTOF and single-cell RNA sequencing and...
9.
Di Giacomo A, Lahn M, Eggermont A, Fox B, Ibrahim R, Sharma P, et al.
Eur J Cancer
. 2024 Jan;
198:113501.
PMID: 38169219
The 2022 yearly Think Tank Meeting in Siena, Tuscany (Italy), organized by the Italian Network for Tumor Biotherapy (NIBIT) Foundation, the Parker Institute for Cancer Immunotherapy and the World Immunotherapy...
10.
Deng N, Reyes-Uribe L, Fahrmann J, Thoman W, Munsell M, Dennison J, et al.
Clin Cancer Res
. 2023 Sep;
29(21):4361-4372.
PMID: 37724990
Purpose: Lynch syndrome (LS) is a hereditary condition with a high lifetime risk of colorectal and endometrial cancers. Exercise is a non-pharmacologic intervention to reduce cancer risk, though its impact...